Neonatal sepsis: Progress towards improved outcomes

Journal of Infection

Volumn 68, Issue SUPPL1, 2014, Pages

  Shane, Andi L ^a,b   Stoll, Barbara J ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

Burden; Management; Neonatal sepsis; Prevention

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BOVINE LACTOFERRIN; FLUCONAZOLE; IMMUNOGLOBULIN G; LACTOFERRIN; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

AMNIONITIS; ARTICLE; CANDIDIASIS; CEREBRAL PALSY; COAGULASE NEGATIVE STAPHYLOCCCUS; EARLY ONSET NEONATAL SEPSIS; ENTERIC FEEDING; ESCHERICHIA COLI; GESTATIONAL AGE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAND WASHING; HEALTHCARE ASSOCIATED INFECTION; HUMAN; IMMATURITY; INVASIVE CANDIDIASIS; LATE ONSET NEONATAL SEPSIS; LATE ONSET SEPSIS; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTICENTER STUDY (TOPIC); MYCOSIS; NEWBORN DEATH; NEWBORN MORBIDITY; NEWBORN MORTALITY; NEWBORN SEPSIS; NONHUMAN; PARENTERAL NUTRITION; PERINATAL PERIOD; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURITY; PROGRAM COST EFFECTIVENESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SKIN CARE; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; VERY LOW BIRTH WEIGHT; VISUAL IMPAIRMENT;

BURDEN; MANAGEMENT; NEONATAL SEPSIS; PREVENTION;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; CANDIDEMIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HEALTH POLICY; HUMANS; INFANT, NEWBORN; INFECTION CONTROL; ORGANIZATIONAL POLICY; RISK FACTORS; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WORLD HEALTH;

EID: 84889648452     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.09.011     Document Type: Article

References (66)

1. Tissières P., Ochoda A., Dunn-Siegrist I., Drifte G., Morales M., Pfister R., et al. Innate immune deficiency of extremely premature neonates can be reversed by interferon-γ. PLoS One 2012, 7:e32863.
2. Wynn J.L., Levy O. Role of innate host defenses in susceptibility to early-onset neonatal sepsis. Clin Perinatol 2010, 37:307-337.
3. Schrag S.J., Stoll B.J. Early-onset neonatal sepsis in the era of widespread intrapartum chemoprophylaxis. Pediatr Infect Dis J 2006, 25:939-940.
4. Schuchat A., Zywicki S., Dinsmoor M., Mercer B., Romaguera J., O'Sullivan M., et al. Risk factors and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study. Pediatrics 2000, 105:21-26.
5. Weston E.J., Pondo T., Lewis M.M., Martell-Cleary P., Morin C., Jewell B., et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatr Infect Dis J 2011, 30:937-941.
6. Stoll B.J., Hansen N.I., Sánchez P.J., Faix R.G., Poindexter B.B., Van Meurs K.P., et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics 2011, 127:817-826.
7. Lim D.V., Morales W.J., Walsh A.F., Kazanis D. Reduction of morbidity and mortality rates for neonatal group B streptococcal disease through early diagnosis and chemoprophylaxis. J Clin Microbiol 1986, 23:489-492.
8. Boyer K.M., Gotoff S.P. Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. N Engl J Med 1986, 314:1665-1669.
9. Heath P.T., Balfour G.F., Tighe H., Verlander N.Q., Lamagni T.L., Efstratiou A., et al. Group B streptococcal disease in infants: a case control study. Arch Dis Child 2009, 94:674-680.
10. Centers for Disease Control and Prevention Prevention of perinatal Group B streptococcal disease: revised guidelines from CDC 2010, 1-36. MMWR2010.
11. Vergnano S., Embleton N., Collinson A., Menson E., Russell A.B., Heath P. Missed opportunities for preventing group B streptococcus infection. Arch Dis Child Fetal Neonatal Ed 2010, 95:F72-F73.
12. Vergnano S., Menson E., Kennea N., Embleton N., Russell A.B., Watts T., et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed 2011, 96:F9-F14.
13. Edmond K.M., Kortsalioudaki C., Scott S., Schrag S.J., Zaidi A.K., Cousens S., et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012, 379:547-556.
14. UK National Screening Committee Screening for Group B Streptococcal infection in pregnancy: external review against programme appraisal criteria for the UK National Screening Committee (UK NSC) 2012.
15. Royal College of Gynaecologists The prevention of early-onset neonatal Group B streptococcal disease 2012, Green-top guideline No36. 2nd ed.
16. Moore M.R., Schrag S.J., Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis 2003, 3:201-213.
17. Stoll B.J., Hansen N., Fanaroff A.A., Wright L.L., Carlo W.A., Ehrenkranz R.A., et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002, 110:285-291.
18. Glasgow T.S., Young P.C., Wallin J., Kwok C., Stoddard G., Firth S., et al. Association of intrapartum antibiotic exposure and late-onset serious bacterial infections in infants. Pediatrics 2005, 116:696-702.
19. Muller-Pebody B., Johnson A.P., Heath P.T., Gilbert R.E., Henderson K.L., Sharland M., et al. Empirical treatment of neonatal sepsis: are the current guidelines adequate?. Arch Dis Child Fetal Neonatal Ed 2011, 96:F4-F8.
20. Stoll B.J., Hansen N., Fanaroff A.A., Wright L.L., Carlo W.A., Ehrenkranz R.A., et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002, 347:240-247.
21. Hornik C.P., Fort P., Clark R.H., Watt K., Benjamin D.K., Smith P.B., et al. Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. Early Hum Dev 2012, 88(Suppl. 2):S69-S74.
22. Cohen-Wolkowiez M., Moran C., Benjamin D.K., Cotten C.M., Clark R.H., Smith P.B. Early and late onset sepsis in late preterm infants. Pediatr Infect Dis J 2009, 28:1052-1056.
23. Healy C.M., Baker C.J., Palazzi D.L., Campbell J.R., Edwards M.S. Distinguishing true coagulase-negative Staphylococcus infections from contaminants in the neonatal intensive care unit. J Perinatol 2013 Jan, 33(1):52-58. http://dx.doi.org/10.1038/jp.2012.36. [Epub 2012 Apr 12].
24. Shane A.L., Hansen N.I., Stoll B.J., Bell E.F., Sánchez P.J., Shankaran S., et al. Methicillin-resistant and susceptible Staphylococcus aureus bacteremia and meningitis in preterm infants. Pediatrics 2012, 129:e914-e922.
25. Leibovitz E. Strategies for the prevention of neonatal candidiasis. Pediatr Neonatol 2012, 53:83-89.
26. Benjamin D.K., Stoll B.J., Fanaroff A.A., McDonald S.A., Oh W., Higgins R.D., et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006, 117:84-92.
27. Fridkin S.K., Kaufman D., Edwards J.R., Shetty S., Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006, 117:1680-1687.
28. Kaufman D.A. Challenging issues in neonatal candidiasis. Curr Med Res Opin 2010, 26:1769-1778.
29. Benjamin D.K., Poole C., Steinbach W.J., Rowen J.L., Walsh T.J. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003, 112:634-640.
30. Benjamin D.K., Stoll B.J., Gantz M.G., Walsh M.C., Sánchez P.J., Das A., et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 2010, 126:e865-e873.
31. Ascher S.B., Smith P.B., Watt K., Benjamin D.K., Cohen-Wolkowiez M., Clark R.H., et al. Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J 2012, 31:439-443.
32. Stoll B.J., Hansen N.I., Adams-Chapman I., Fanaroff A.A., Hintz S.R., Vohr B., et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. J Am Med Assoc 2004, 292:2357-2365.
33. Damjanovic V., Connolly C.M., van Saene H.K., Cooke R.W., Corkill J.E., van Belkum A., et al. Selective decontamination with nystatin for control of a Candida outbreak in a neonatal intensive care unit. J Hosp Infect 1993, 24:245-259.
34. Ozturk M.A., Gunes T., Koklu E., Cetin N., Koc N. Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit. Mycoses 2006, 49:484-492.
35. Aydemir C., Oguz S.S., Dizdar E.A., Akar M., Sarikabadayi Y.U., Saygan S., et al. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 2011, 96:F164-F168.
36. Kaufman D., Boyle R., Hazen K.C., Patrie J.T., Robinson M., Donowitz L.G. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001, 345:1660-1666.
37. Healy C.M., Campbell J.R., Zaccaria E., Baker C.J. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 2008, 121:703-710.
38. Bertini G., Perugi S., Dani C., Filippi L., Pratesi S., Rubaltelli F.F. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr 2005, 147:162-165.
39. Healy C.M., Baker C.J., Zaccaria E., Campbell J.R. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr 2005, 147:166-171.
40. Kaufman D. Fluconazole prophylaxis decreases the combined outcome of invasive Candida infections or mortality in preterm infants. Pediatrics 2008, 122:1158-1159. [author reply 9].
41. Manzoni P., Stolfi I., Pugni L., Decembrino L., Magnani C., Vetrano G., et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007, 356:2483-2495.
42. Uko S., Soghier L.M., Vega M., Marsh J., Reinersman G.T., Herring L., et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 2006, 117:1243-1252.
43. Clerihew L., Austin N., McGuire W. prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weigh infants. Cochrane Database Syst Rev 2007 Oct, 17(4):CD003850.
44. Pickering L., American Academy of Pediatrics Red Book: 2012 report of the committee on infectious diseases 2012, American Academy of Pediatrics, Elk Grove Village, IL. 29th ed.
45. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
46. Kaufman D., Fairchild K.D. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev 2004, 17:638-680. [table of contents].
47. Noyola D.E., Fernandez M., Moylett E.H., Baker C.J. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 2001, 32:1018-1023.
48. Dudeck M.A., Horan T.C., Peterson K.D., Allen-Bridson K., Morrell G., Pollock D.A., et al. National Healthcare Safety Network (NHSN) report, data summary for 2010, device-associated module. Am J Infect Control 2011, 39:798-816.
49. Sohn A.H., Garrett D.O., Sinkowitz-Cochran R.L., Grohskopf L.A., Levine G.L., Stover B.H., et al. Prevalence of nosocomial infections in neonatal intensive care unit patients: results from the first national point-prevalence survey. J Pediatr 2001, 139:821-827.
50. Stoll B.J., Hansen N.I., Bell E.F., Shankaran S., Laptook A.R., Walsh M.C., et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010, 126:443-456.
51. Pammi M., Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia. Cochrane Database Syst Rev 2011, CD003956.
52. Del Vecchio A., Christensen R.D. Neonatal neutropenia: what diagnostic evaluation is needed and when is treatment recommended?. Early Hum Dev 2012, 88(Suppl. 2):S19-S24.
53. El-Ganzoury M.M., El-Farrash R.A., Saad A.A., Mohamed A.G., El-Sherbini I.G. Invivo effect of recombinant human granulocyte colony-stimulating factor on neutrophilic expression of CD11b in septic neonates: a randomized controlled trial. Pediatr Hematol Oncol 2012, 29:272-284.
54. Carr R., Modi N., Doré C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev 2003, CD003066.
55. Napolitano L.M. Immune stimulation in sepsis: to be or not to be?. Chest 2005, 127:1882-1885.
56. Brocklehurst P., Farrell B., King A., Juszczak E., Darlow B., Haque K., et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 2011, 365:1201-1211.
57. Ohlsson A., Lacy J. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev 2010, CD001239.
58. Haque K.N., Pammi M. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev 2011, CD004205.
59. Powers R.J., Wirtschafter D.W. Decreasing central line associated bloodstream infection in neonatal intensive care. Clin Perinatol 2010, 37:247-272.
60. Schulman J., Stricof R., Stevens T.P., Horgan M., Gase K., Holzman I.R., et al. Statewide NICU central-line-associated bloodstream infection rates decline after bundles and checklists. Pediatrics 2011, 127:436-444.
61. Manzoni P., Rinaldi M., Cattani S., Pugni L., Romeo M.G., Messner H., et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. J Am Med Assoc 2009, 302:1421-1428.
62. Pammi M., Abrams S.A. Oral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev 2011, CD007138.
63. Glass H.C., Bonifacio S.L., Chau V., Glidden D., Poskitt K., Barkovich A.J., et al. Recurrent postnatal infections are associated with progressive white matter injury in premature infants. Pediatrics 2008, 122:299-305.
64. Shah D.K., Lavery S., Doyle L.W., Wong C., McDougall P., Inder T.E. Use of 2-channel bedside electroencephalogram monitoring in term-born encephalopathic infants related to cerebral injury defined by magnetic resonance imaging. Pediatrics 2006, 118:47-55.
65. Schlapbach L.J., Aebischer M., Adams M., Natalucci G., Bonhoeffer J., Latzin P., et al. Impact of sepsis on neurodevelopmental outcome in a Swiss National Cohort of extremely premature infants. Pediatrics 2011, 128:e348-e357.
66. van der Ree M., Tanis J.C., Van Braeckel K.N., Bos A.F., Roze E. Functional impairments at school age of preterm born children with late-onset sepsis. Early Hum Dev 2011, 87:821-826.